research report · ISRG

Intuitive Surgical Inc

Johannes Vermeer, Woman Holding a Balance, c. 1664, detail · National Gallery of Art

Viridis’s deep research report, written Nov 1, 2026 from its quarterly report (10-Q for the quarter ended Sep 30, 2026, filed Oct 21, 2026). Written and checked with Anthropic’s Claude models.

your email, no card; what you get

business trajectory

Improving

better on balance: sales, margins, cash or competitive position

financial resilience

Strong

can meet its obligations and fund its plan for two years with money it can count on, with room

Judgments of the business from its filings, not of its shares: no valuation, no advice.

bottom line

Intuitive's business got stronger in the third quarter of 2026. The fall in reported profit comes from a one-time legal settlement, not from weaker operations. Revenue rose 22% to $3.05B. Excluding $454.9M of litigation charges, operating margin was about 34%, against about 31% a year earlier (my calculation). Two pressures stand against that: U.S. procedure growth slowed to 10%, and planned price actions are expected to cut instrument revenue per procedure by about 3% to 5% once fully in place. The company has no debt and $6.80B of cash and investments, so its finances are secure, although nine-month buybacks ran well ahead of free cash flow.

what changed this quarter

  • Revenue was $3,048.7M against $2,505.1M a year earlier. Da Vinci procedures were about 906,000 (+14%) and Ion procedures about 49,700 (+31%).
  • GAAP operating income fell 22% to $592.6M and diluted earnings per share fell to $1.49 from $1.95. Both absorb a $450M charge to settle the hospital antitrust class action, which still needs court approval.
  • The company placed 546 da Vinci systems against 427, including 315 da Vinci 5.
  • Guidance changed as follows:
  • Procedure growth narrowed to 14%–15% from 13.5%–15.5%.
  • Non-GAAP gross margin raised to 68.7%–69.3% from 68%–69%.
  • Operating expense growth kept at 11%–13%.
  • The company bought back 7.8M shares for $2.94B, at an average of $377.01. About $1.8B of authorization remains.

in the full report

Its findings, each with the evidence, the strongest counterpoint and what would prove it wrong:

  • Underlying profitability improved; the earnings drop is the settlement
  • U.S. volume is slowing just as pricing turns from tailwind to headwind
  • Buybacks are drawing down the cash pile, and cash flow is flattered by timing
  • Litigation risk was narrowed, not removed

Then its finances, the quality of its earnings, its management, the case for and against, and what to watch, its claims cited to the filings and checked against them.

read it whole

Your email and the code we send it, no card. The report then opens: a free account has 2 free reports a month from the library, the reports already written. Already have a Viridis account? Use its email, and the report goes on it. You also see what ISRG files, free: its deadlines and its red flags.

Subscribe: your plan’s reports work on any company that files with the SEC, written for you if nobody has asked yet, and each new one on the companies you choose comes as they file.

In Claude or ChatGPT, ask: “What does Viridis's report on ISRG say?” Add Viridis to Claude, or to ChatGPT.